Dexcom (DXCM) Return on Capital Employed (2011 - 2026)

Dexcom (DXCM) has 16 years of Return on Capital Employed data on file, last reported at 24.24% in Q1 2026.

• Return on Capital Employed for Q1 2026 came in at 24.24%, up 658.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 24.24% (up 658.0% YoY), and the FY2025 annual result was 21.36%, up 393.0% from the prior year.
• Return on Capital Employed advanced to 24.24% in Q1 2026 per DXCM's latest filing, from 19.09% in the prior quarter.
• Over five years, Return on Capital Employed peaked at 24.24% in Q1 2026 and troughed at 5.48% in Q2 2022.
• A 5-year average of 13.55% and a median of 12.97% in 2024 frame the typical range for Return on Capital Employed.
• The sharpest annual moves came in 2022 and 2026: Return on Capital Employed sank 349 bps in 2022, then soared 658 bps in 2026.
• A 5-year view of Return on Capital Employed shows it stood at 11.83% in 2022, then advanced by 4 bps to 12.26% in 2023, then soared by 40 bps to 17.21% in 2024, then advanced by 11 bps to 19.09% in 2025, then rose by 27 bps to 24.24% in 2026.
• Business Quant data shows DXCM's Return on Capital Employed at 24.24% in Q1 2026, 19.09% in Q4 2025, and 19.07% in Q3 2025.